CL2020000812A1 - Semaglutida en la terapia médica. - Google Patents

Semaglutida en la terapia médica.

Info

Publication number
CL2020000812A1
CL2020000812A1 CL2020000812A CL2020000812A CL2020000812A1 CL 2020000812 A1 CL2020000812 A1 CL 2020000812A1 CL 2020000812 A CL2020000812 A CL 2020000812A CL 2020000812 A CL2020000812 A CL 2020000812A CL 2020000812 A1 CL2020000812 A1 CL 2020000812A1
Authority
CL
Chile
Prior art keywords
semaglutide
medical therapy
therapy
medical
weight
Prior art date
Application number
CL2020000812A
Other languages
English (en)
Spanish (es)
Inventor
Maria Kabisch
Thomas Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60083831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000812(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2020000812A1 publication Critical patent/CL2020000812A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2020000812A 2017-10-12 2020-03-27 Semaglutida en la terapia médica. CL2020000812A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17196254 2017-10-12

Publications (1)

Publication Number Publication Date
CL2020000812A1 true CL2020000812A1 (es) 2020-08-14

Family

ID=60083831

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000812A CL2020000812A1 (es) 2017-10-12 2020-03-27 Semaglutida en la terapia médica.

Country Status (18)

Country Link
US (4) US12029779B2 (https=)
EP (1) EP3694538A1 (https=)
JP (2) JP7148605B2 (https=)
KR (1) KR20200069316A (https=)
CN (4) CN119838000A (https=)
AU (2) AU2018348929B2 (https=)
BR (1) BR112020006246A2 (https=)
CA (1) CA3078652A1 (https=)
CL (1) CL2020000812A1 (https=)
IL (3) IL322969A (https=)
MA (1) MA50358A (https=)
MX (3) MX2020003049A (https=)
MY (1) MY204827A (https=)
PH (1) PH12020550185A1 (https=)
SG (1) SG11202002841PA (https=)
TW (1) TWI842681B (https=)
WO (1) WO2019072941A1 (https=)
ZA (3) ZA202503350B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078652A1 (en) * 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
CN115484935A (zh) 2020-02-14 2022-12-16 G2G生物公司 包括含有glp-1类似物或其药学上可接受的盐的缓释微球的药物组合物
JP7761567B2 (ja) * 2020-02-18 2025-10-28 ノヴォ ノルディスク アー／エス 医薬製剤
US11478533B2 (en) * 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022212271A1 (en) * 2021-03-29 2022-10-06 Sanford Health Methods and compositions for treating lysosomal storage disorders
CN119317635A (zh) * 2022-06-08 2025-01-14 载度思生命科学有限公司 用于2型糖尿病和体重管理的可重复使用的多剂量可变剂量的单一笔式注射器
WO2024249659A2 (en) * 2023-05-30 2024-12-05 The Medical College Of Wisconsin, Inc. Methods for weight loss and/or reducing weight gain
US12597496B2 (en) * 2023-06-05 2026-04-07 Closed Loop Medicine Ltd. Dosing of incretin pathway drugs

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO2003002136A2 (en) 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
BR122019021416A2 (https=) 2003-09-19 2019-12-21
DK3300721T4 (da) 2003-11-20 2025-03-03 Novo Nordisk As Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
MX2007005521A (es) 2004-11-12 2007-05-18 Novo Nordisk As Formulaciones estables de peptidos insulinotropicos.
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
CN104324362B (zh) 2005-09-14 2018-04-24 曼金德公司 以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
KR101438839B1 (ko) 2006-04-14 2014-10-02 맨카인드 코포레이션 글루카곤 유사 펩타이드 1 （ｇｌｐ-1） 약제학적 제제
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
CA2677852A1 (en) 2007-03-20 2008-09-25 Nippon Kayaku Kabushiki Kaisha Method to monitor drug efficacy in diabetic patients using an assay for 1,5-anhydro-d-glucitol
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
PT2373681T (pt) 2008-12-10 2017-04-11 Glaxosmithkline Llc Composições farmacêuticas de albiglutida
AU2010212823B2 (en) 2009-02-13 2016-01-28 Boehringer Ingelheim International Gmbh Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2012016419A1 (zh) 2010-08-06 2012-02-09 浙江贝达药业有限公司 Glp-1衍生物及其应用
SI2651398T1 (en) 2010-12-16 2018-04-30 Novo Nordisk A/S SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
WO2012088379A2 (en) 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102718858B (zh) 2011-03-29 2014-07-02 天津药物研究院 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CN102229668A (zh) 2011-06-03 2011-11-02 浙江贝达药业有限公司 一种glp-1衍生物及其应用
WO2012177929A2 (en) 2011-06-24 2012-12-27 Amylin Pharmaceuticals, Inc. Methods for treating diabetes with extended release formulations of glp-1 receptor agonists
PT2753312T (pt) 2011-09-08 2017-02-03 Mereo Biopharma 2 Ltd Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
EP4338805B1 (en) 2012-06-29 2025-06-04 Amarin Pharmaceuticals Ireland Limited Eicosapentaenoic acid ethyl ester for use in reducing the risk of non-fatal myocardial infarction in a subject on statin therapy
EP2866825B1 (en) 2012-07-01 2020-04-08 Novo Nordisk A/S Use of long-acting glp-1 peptides
KR102272671B1 (ko) * 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy

Also Published As

Publication number Publication date
CN120241968A (zh) 2025-07-04
US20250235511A1 (en) 2025-07-24
ZA202503387B (en) 2025-09-25
TW201914611A (zh) 2019-04-16
TWI842681B (zh) 2024-05-21
EP3694538A1 (en) 2020-08-19
CN111212657A (zh) 2020-05-29
CA3078652A1 (en) 2019-04-18
US20240415935A1 (en) 2024-12-19
US20240316159A1 (en) 2024-09-26
RU2020114960A3 (https=) 2022-02-11
ZA202503350B (en) 2025-09-25
WO2019072941A1 (en) 2019-04-18
MY204827A (en) 2024-09-18
AU2025203535A1 (en) 2025-06-05
ZA202503388B (en) 2025-09-25
JP7475398B2 (ja) 2024-04-26
MX2020003049A (es) 2020-07-27
SG11202002841PA (en) 2020-04-29
CN119950682A (zh) 2025-05-09
CN119838000A (zh) 2025-04-18
MX2025002188A (es) 2025-04-02
IL322968A (en) 2025-10-01
US12029779B2 (en) 2024-07-09
IL322969A (en) 2025-10-01
AU2018348929A1 (en) 2020-05-07
JP2020536854A (ja) 2020-12-17
PH12020550185A1 (en) 2021-03-01
MA50358A (fr) 2020-08-19
JP2022132414A (ja) 2022-09-08
JP7148605B2 (ja) 2022-10-05
US12551536B2 (en) 2026-02-17
BR112020006246A2 (pt) 2021-03-30
US12295988B2 (en) 2025-05-13
US20200237876A1 (en) 2020-07-30
RU2020114960A (ru) 2021-10-28
IL273470A (en) 2020-05-31
KR20200069316A (ko) 2020-06-16
AU2018348929B2 (en) 2025-02-27
MX2025002189A (es) 2025-04-02

Similar Documents

Publication Publication Date Title
CL2020000812A1 (es) Semaglutida en la terapia médica.
ECSP17021754A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX2017004708A (es) Tratamiento del cáncer con agonista de tlr9 con inhibidores de punto de control.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX369041B (es) Proteinas quimericas tipo fosfatasa alcalina.
BR112017013608A2 (pt) picolinamidas como fungicidas
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
MX378108B (es) Anticuerpos anti-met y composiciones.
AR102658A1 (es) Composición para el tratamiento de telas
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2019012938A (es) Uso del inhibidor mejorador de homologo zeste 2 (ezh2) combinado con el inhibidor tirosina cinasa de bruton (btk) en la preparacion de farmacos para tratar tumores.
CL2016002779A1 (es) Composición para el cuidado de la piel
MX381944B (es) Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos.
CR20160565A (es) Derivados de naftiridinadiona
DOP2016000311A (es) Nuevos compuestos
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
BR112017009358A2 (pt) imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.